The FDA might get tougher in monitoring follow-up studies on approved drugs, after an advisory panel recommended to revoke Avastin's "accelerated approval" for advanced breast cancer. The agency decided in June to pull a leukemia treatment off the market that had been granted accelerated approval a decade ago because a follow-up trial showed no clinical benefit and a higher death risk.

Related Summaries